Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Arctic Vision Raises $32 Million for Ophthalmology Drugs in China

publication date: Jul 14, 2020

Arctic Vision, a Shanghai clinical-stage biotech incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China last year, announced a $32 million Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision develops novel ophthalmology therapies for China and Asia. Its first therapy is ARVN001, which is intended to treat macular edema associated with uveitis. The drug is delivered to the suprachoroidal space via a proprietary SCS microinjector. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital